Abera Bioscience AB - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 18 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Abera Bioscience AB - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Abera Bioscience AB - Product Pipeline Review - 2014', provides an overview of the Abera Bioscience AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Abera Bioscience AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Abera Bioscience AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Abera Bioscience AB's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Abera Bioscience AB's pipeline products

Reasons to buy

- Evaluate Abera Bioscience AB's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Abera Bioscience AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Abera Bioscience AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Abera Bioscience AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Abera Bioscience AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Abera Bioscience AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Abera Bioscience AB Snapshot 4
Abera Bioscience AB Overview 4
Key Information 4
Key Facts 4
Abera Bioscience AB - Research and Development Overview 5
Key Therapeutic Areas 5
Abera Bioscience AB - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Abera Bioscience AB - Pipeline Products Glance 9
Abera Bioscience AB - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Abera Bioscience AB - Drug Profiles 10
chlamydia vaccine 10
Product Description 10
Mechanism of Action 10
R&D Progress 10
influenza vaccine 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
pneumococcal vaccine (multivalent) 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
tuberculosis vaccine 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Abera Bioscience AB - Pipeline Analysis 14
Abera Bioscience AB - Pipeline Products by Route of Administration 14
Abera Bioscience AB - Pipeline Products by Molecule Type 15
Abera Bioscience AB - Locations and Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
Coverage 17
Secondary Research 17
Primary Research 17
Expert Panel Validation 17
Contact Us 18
Disclaimer 18

List of Tables
Abera Bioscience AB, Key Information 4
Abera Bioscience AB, Key Facts 4
Abera Bioscience AB - Pipeline by Indication, 2014 6
Abera Bioscience AB - Pipeline by Stage of Development, 2014 7
Abera Bioscience AB - Monotherapy Products in Pipeline, 2014 8
Abera Bioscience AB - Preclinical, 2014 9
Abera Bioscience AB - Pipeline by Route of Administration, 2014 14
Abera Bioscience AB - Pipeline by Molecule Type, 2014 15